This clinical trial is focused on studying a type of breast cancer known as triple negative breast cancer. This form of cancer does not have receptors for estrogen, progesterone, or HER2, which are common targets for cancer treatments. The study is exploring the use of a medication called Imatinib, which is taken orally in the form of a hard capsule. Imatinib is a type of drug known as a protein tyrosine kinase inhibitor, which works by blocking certain proteins that can promote the growth of cancer cells.

The purpose of the study is to see if Imatinib can change triple negative breast cancer into a type that has estrogen receptors, known as ER-positive breast cancer. This change could potentially make the cancer more responsive to treatments that target estrogen receptors. Participants in the study will take Imatinib for a period of time before undergoing surgery to remove the breast cancer tissue. The researchers will then examine the removed tissue to determine if the cancer has converted to ER-positive.

Throughout the study, the safety of Imatinib will be monitored, and researchers will also look for markers that might predict whether the cancer will convert to ER-positive. This involves analyzing the molecular characteristics of the cancer, such as gene expression and immune response, both before starting Imatinib and after the surgery. The study aims to provide valuable insights into the potential of Imatinib as a treatment option for patients with triple negative breast cancer.